Physiomics PLCLSE Physiomics

Physiomics Plc engages in the provision of outsourced systems and computational biology services to pharmaceutical companies. The company is headquartered in Oxford, Oxfordshire and currently employs 8 full-time employees. The company went IPO on 2004-12-20. The Company’s Virtual Tumour technology uses computer modeling to predict the effects of cancer drugs and treatments to improve its drug discovery and development projects. The Company’s Virtual Tumour software platform is used to simulate the effects of anti-cancer agents on pre-clinical and human tumors. The company is used by companies ranging from startup biotech to global large-cap pharmaceuticals. The company offers services, including exposure-response modeling, mechanism of action modeling, data analysis and visualization, translational modeling, tumor growth inhibition modeling, physiologically based pharmacokinetic (PBPK) modeling, population pharmacokinetics (PK) and neurocirculatory asthenia (NCA), and clinical trial simulation. The firm is focused on developing a tool for the personalization of docetaxel dosing in late-stage prostate cancer.